Abstract:The overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway has been examined in various carcinomas and is reported to be significantly correlated with prognosis. However, little is known with regard to the PI3K/Akt signal transduction pathway in advanced non-small cell lung carcinoma (NSCLC). The present study investigated the expression of PI3K and phosphorylated (p)-Akt protein and its clinical significance in NSCLC. The clinical records of 157 patients with NSCLC (70 stage I-IIIA and 87 stage IIIB-IV cases), consisting of 75 cases of squamous cell carcinoma and 82 cases of adenocarcinoma, together with 30 resected lung cancer tumor-adjacent tissue samples, were retrospectively evaluated. PI3K and p-Akt expression in the NSCLC and tumor-adjacent tissues were measured using an immunohistochemical method, and its correlation with the clinicopathological data and prognosis in advanced NSCLC was evaluated. PI3K and p-Akt expression was significantly higher in the cancer tissues (chi(2)=14.8455; P=0.001) than in the tumor-adjacent tissues (chi(2)=14.2615; P=0.001). The overexpression of p-Akt in stage I-IIIA NSCLC was associated with lymph node metastasis (chi(2)=6.1189; P=0.013) and tumor-node-metastasis (TNM) stage (chi(2)=8.9752; P=0.011), however, no correlation was observed with gender, age, pathological type and histological grade. The overexpression of p-Akt in stage IIIB-IV NSCLC was only associated with TNM stage (chi(2)=5.7501; P=0.016), and no correlation was observed with gender, age, Pathological type, histological grade and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The overexpression of PI3K was not found to correlate with the aforementioned clinicopathological variables in all patients. Survival was significantly improved in advanced NSCLC with PI3K- and p-Akt-negative expression compared with PI3K- and p-Akt-positive expression [P13K: 17.70 months (95% confidence interval (CI), 15.11-20.28 mont hs) vs. 13.43 months (95% CI, 11.83-15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93-19.34 months) vs. 13.07 months (95% CI, 11.32-14.82 months); P=0.007]. Multivariate analysis showed that PI3K [hazard ratio (HR)=2.143; 95% CI, 1.211-3.790; P=0.009], p-Akt (HR=1.991; 95% CI, 1.009-3.927; P=0.047), TNM stage (HR=4.788; 95% CI, 2.591-8.848; P=0.001) and ECOG-PS (HR=3.272; 95% CI, 1.701-6.296; P=0.001) were independent predictors for survival in stage IIIB-IV NSCLC. These results indicated that p-Akt overexpression closely correlates with factors of an unfavorable prognosis in NSCLC. PI3K and p-Akt overexpression are independent markers of a poor prognosis in advanced NSCLC.

Expression and Prognostic Value of AKT2 in Non-small Cell Lung Cancer

[The Expression and Clinical Significance of AKT2, Phosphorylated AKT2 in Non-Small Cell Lung Cancer].

Expression of AKT2 Gene in Human Liver Cancer and Its Clinical Significance

[Phophorylated Akt Protein Expression in Non-Small Cell Lung Cancer].

The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: a Meta-Analysis.

Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer

Proline-rich Tyrosine Kinase 2 and Its Phosphorylated Form Py881 Are Novel Prognostic Markers for Non-Small-cell Lung Cancer Progression and Patients’ Overall Survival

Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.

Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma.

Analysis of the overall survival time between the different expression of AKT1 and AKT2 in gliomas

Expression of ATM , CHK 2 and BRCA 1 predicts the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy

Detection of Phosphorylated AKT Expression and Cell Proliferation in Non-Small Cell Lung Cancer Tissue

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Expressions of Phosphorylated AKT and Phosphorylated EGFR in Non-Small Cell Lung Cancer and Their Significance

Progression and Prognostic Value of ECT2 in Non-Small-cell Lung Cancer and Its Correlation with PCNA.

P70.03 Molecular Characterization of AKT1 Gene in East Asian Non-Small Cell Lung Cancer Patients

Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis

AKT2 Expression is Associated with Glioma Malignant Progression and Required for Cell Survival and Invasion.

Activating Transcription Factor 2 Expression Mediates Cell Proliferation and is Associated with Poor Prognosis in Human Non-Small Cell Lung Carcinoma.

Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer

Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer